Answers are grounded in this paper and cite their sources.
Cross-sectional study finds lower serum vitamin D levels track with neuropathic pain in adults with musculoskeletal pain, suggesting a link between vitamin status and nerve symptoms.
Background/Objectives: The association between vitamin D status and neuropathic pain in musculoskeletal disorders remains uncertain. This study examined the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and neuropathic pain features in adults with musculoskeletal pain. Methods: This single-center analytical cross-sectional study included 300 adults aged 18–79 years who presented between June and December 2024. Participants were classified as vitamin D deficient (<20 ng/mL; n = 105), insufficient (20–<30 ng/mL; n = 117), or sufficient (≥30 ng/mL; n = 78). Neuropathic pain was assessed using DN4, LANSS, painDETECT, and the Short-Form McGill Pain Questionnaire. Multivariable logistic regression adjusted for age, sex, body mass index, diabetes mellitus, inflammatory rheumatic disease, cervical/lumbar discopathy, and fibromyalgia. Results: Neuropathic pain scores increased as 25(OH)D levels decreased. DN4 positivity occurred in 53.3%, 43.6%, and 25.6% of the deficient, insufficient, and sufficient groups, respectively (p < 0.001). Compared with sufficiency, vitamin D deficiency and insufficiency were associated with DN4 positivity (adjusted odds ratio [aOR] 3.53, 95% confidence interval [CI] 1.76–7.08; and aOR 2.38, 95% CI 1.22–4.64, respectively). Each 10ng/mL decrease in 25(OH)D was associated with 46% higher odds of DN4 positivity (aOR 1.46, 95% CI 1.14–1.86). Similar associations were observed for LANSS and painDETECT ≥13 and persisted in sensitivity analyses. Conclusions: Lower 25(OH)D levels were associated with higher neuropathic pain scores and more frequent positive screens. The cross-sectional design, modest effect sizes, and unmeasured supplementation and calcium–parathyroid hormone variables preclude conclusions regarding causality, diagnostic utility, or treatment efficacy.
No takes yet. Share an insight, caveat, or question.
Satilmis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: